Company News: Pfizer

Share this article:
Pfizer said last night that it suspended the osteoarthritis clinical program for investigational compound tanezumab following a certain number of reports that tanezumab patients had their osteoarthritis worsen leading to joint replacement. The product was being studied as a way to treat pain associated with the condition. Pfizer said the adverse event has not been observed in non-osteoarthritis patient populations taking tanezumab. Pfizer said the monoclonal antibody is still being studied in conditions such as cancer pain, low back pain and pain associated with diabetes.
Share this article:

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.